These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 17765647)

  • 21. Long-term clinical outcomes after sirolimus-eluting stent implantation for treatment of restenosis within bare-metal versus drug-eluting stents.
    Whan Lee C; Kim SH; Suh J; Park DW; Lee SH; Kim YH; Hong MK; Kim JJ; Park SW; Park SJ
    Catheter Cardiovasc Interv; 2008 Apr; 71(5):594-8. PubMed ID: 18311841
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prophylactic abciximab in elective coronary stenting: results of a randomized trial.
    Tamburino C; Russo G; Nicosia A; Galassi AR; Foti R; Scriffignano V; Kereiakes DJ; Giuffrida G
    J Invasive Cardiol; 2002 Feb; 14(2):72-9. PubMed ID: 11818641
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Abciximab administration and clinical outcomes after percutaneous intervention for in-stent restenosis.
    Moustapha A; Assali AR; Sdringola S; Yusuf SW; Vaughn WK; Fish RD; Schroth GW; Krajcer Z; Rosales OR; Smalling RW; Anderson HV
    Catheter Cardiovasc Interv; 2002 Jun; 56(2):184-7. PubMed ID: 12112910
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimizing percutaneous coronary revascularization in diabetic women: analysis from the EPISTENT trial.
    Cho L; Marso SP; Bhatt DL; Topol EJ
    J Womens Health Gend Based Med; 2000 Sep; 9(7):741-6. PubMed ID: 11025866
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcomes of diabetics receiving bare-metal stents versus drug-eluting stents.
    Ramanath VS; Brown JR; Malenka DJ; DeVries JT; Sidhu MS; Robb JF; Jayne JE; Hettleman BD; Friedman BJ; Niles NW; Kaplan AV; Thompson CA;
    Catheter Cardiovasc Interv; 2010 Oct; 76(4):473-81. PubMed ID: 20882647
    [TBL] [Abstract][Full Text] [Related]  

  • 26. One-year outcome of patients with diabetes mellitus after percutaneous coronary intervention with three different revascularization strategies: results from the Diabetic Argentina Registry (DEAR).
    Mieres J; Fernandez-Pereira C; Risau G; Solorzano L; Pauletto R; Rodriguez-Granillo AM; Rubilar B; Stella P; Rodriguez AE
    Cardiovasc Revasc Med; 2012; 13(5):265-71. PubMed ID: 22796496
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting.
    Merlini PA; Rossi M; Menozzi A; Buratti S; Brennan DM; Moliterno DJ; Topol EJ; Ardissino D
    Circulation; 2004 May; 109(18):2203-6. PubMed ID: 15117843
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Unexpected mortality reduction with abciximab for in-stent restenosis.
    Mukherjee D; Reginelli JP; Moliterno DJ; Yadav JS; Schneider JP; Raymond R; Whitlow PL; Franco I; Topol EJ; Ellis SG
    J Invasive Cardiol; 2000 Nov; 12(11):540-4. PubMed ID: 11060563
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Angiographic and clinical outcomes of rosiglitazone in patients with type 2 diabetes mellitus after percutaneous coronary interventions: a single center experience.
    Fang CC; Ng Jao YT; Yi-Chen ; Yu CL; Chen CL; Wang SP
    Angiology; 2007; 58(5):523-34. PubMed ID: 18024934
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stenting of coronary bifurcation lesions by using modified crush technique with double kissing balloon inflation (sleeve technique): immediate procedure result and short-term clinical outcomes.
    Jim MH; Ho HH; Chan AO; Chow WH
    Catheter Cardiovasc Interv; 2007 Jun; 69(7):969-75. PubMed ID: 17290438
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dexamethasone-eluting stents for the prevention of in-stent restenosis: evidence for a differential effect in insulin-dependent and non-insulin-dependent diabetic patients.
    van der Hoeven BL; Pires NM; Warda HM; Putter H; Quax PH; Schalij MJ; Jukema JW
    Int J Cardiol; 2008 Feb; 124(2):166-71. PubMed ID: 17408773
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of abciximab on clinical and angiographic restenosis in patients with non-ST-segment elevation acute coronary syndromes.
    Iijima R; Ndrepepa G; Mehilli J; Dirschinger J; Pache J; Seyfarth M; Schömig A; Kastrati A
    Am J Cardiol; 2008 May; 101(9):1226-31. PubMed ID: 18435948
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of postprocedure minimum stent area on long-term results following abciximab-coated stent implantation: an intravascular ultrasound analysis.
    Hong YJ; Jeong MH; Hwang SH; Yun NS; Lim SY; Lee SR; Hong SN; Kim KH; Park HW; Kim JH; Kim W; Ahn YK; Cho JG; Park JC; Kang JC
    Int J Cardiol; 2007 Dec; 123(1):23-8. PubMed ID: 17289173
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment synergy of silicon carbide-coated stenting and abciximab for complex coronary artery lesions: clinical results of a single-center study.
    van der Vleuten PA; Wijpkema JS; van den Heuvel AF; Bosma CA; Jessurun GA; Tio RA
    Ital Heart J; 2004 Sep; 5(9):663-6. PubMed ID: 15568593
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term results after drug-eluting stent implantation in diabetic patients according to diabetic treatment.
    Voudris V; Karyofillis P; Thomopoulou S; Doulaptsis C; Manginas A; Pavlides G; Cokkinos DV
    Hellenic J Cardiol; 2011; 52(1):15-22. PubMed ID: 21292603
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug eluting stents versus PTA with GP IIb/IIIa blockade below the knee in patients with current ulcers--The BELOW Study.
    Tepe G; Schmehl J; Heller S; Brechtel K; Heuschmid M; Fenchel M; Kramer U; Miller S; Claussen CD
    J Cardiovasc Surg (Torino); 2010 Apr; 51(2):203-12. PubMed ID: 20354490
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Why diabetics are at risk in percutaneous coronary intervention and the appropriate management of diabetics in interventional cardiology.
    Reginelli JP; Bhatt DL
    J Invasive Cardiol; 2002 Dec; 14 Suppl E():2E-10E; quiz 11E. PubMed ID: 12668857
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of chronic kidney disease and diabetes on percutaneous coronary intervention outcomes.
    Lepor NE
    Rev Cardiovasc Med; 2006; 7 Suppl 4():S38-48. PubMed ID: 17224890
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Abciximab-facilitated percutaneous coronary intervention and long-term survival--a prospective single-center registry.
    Brener SJ; Ellis SG; Schneider J; Apperson-Hansen C; Topol EJ
    Eur Heart J; 2003 Apr; 24(7):630-8. PubMed ID: 12657221
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Usefulness of abciximab for treatment of early coronary artery stent thrombosis.
    Casserly IP; Hasdai D; Berger PB; Holmes DR; Schwartz RS; Bell MR
    Am J Cardiol; 1998 Oct; 82(8):981-5. PubMed ID: 9794358
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.